Clinical Trial Update: Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

This document reports the termination of a Phase 1 single-dose escalation trial of 131I-labeled sibrotuzumab in patients with advanced or metastatic non-small c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• 131I-Sibrotuzumab (sibrotuzumab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: TERMINATED